412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v).
Saved in:
| Title: | 412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v). |
|---|---|
| Authors: | Melero, I1 (AUTHOR), Alvarez, E Castanon2 (AUTHOR), Mau-Sorensen, M3 (AUTHOR), Lassen, U N4 (AUTHOR), Lolkema, M P5 (AUTHOR), Robbrecht, D G6 (AUTHOR), Gomez-Roca, C A7 (AUTHOR), Martin-Liberal, J8 (AUTHOR), Tabernero, J9 (AUTHOR), Ros, W10 (AUTHOR) |
| Source: | Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 133286259 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Melero%2C+I%22">Melero, I</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Alvarez%2C+E+Castanon%22">Alvarez, E Castanon</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mau-Sorensen%2C+M%22">Mau-Sorensen, M</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lassen%2C+U+N%22">Lassen, U N</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lolkema%2C+M+P%22">Lolkema, M P</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Robbrecht%2C+D+G%22">Robbrecht, D G</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gomez-Roca%2C+C+A%22">Gomez-Roca, C A</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martin-Liberal%2C+J%22">Martin-Liberal, J</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tabernero%2C+J%22">Tabernero, J</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ros%2C+W%22">Ros, W</searchLink><relatesTo>10</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=133286259 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/annonc/mdy279.400 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: N.PAG Titles: – TitleFull: 412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Melero, I – PersonEntity: Name: NameFull: Alvarez, E Castanon – PersonEntity: Name: NameFull: Mau-Sorensen, M – PersonEntity: Name: NameFull: Lassen, U N – PersonEntity: Name: NameFull: Lolkema, M P – PersonEntity: Name: NameFull: Robbrecht, D G – PersonEntity: Name: NameFull: Gomez-Roca, C A – PersonEntity: Name: NameFull: Martin-Liberal, J – PersonEntity: Name: NameFull: Tabernero, J – PersonEntity: Name: NameFull: Ros, W IsPartOfRelationships: – BibEntity: Dates: – D: 04 M: 10 Text: 2018 Supplement Type: published Y: 2018 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 29 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
